Major U.S. stock indexes closed mixed on Thursday, February 26, 2026, with technology shares under pressure even as broader cyclicals and small caps showed resilience. The session highlighted ongoing investor tension between enthusiasm for AI-driven growth and concern about stretched valuations and…
US stocks extended this week’s rebound on Wednesday, February 25, 2026, with a tech-led advance ahead of and then through Nvidia’s blockbuster earnings release after the bell.finance.yahoo+5
Index performance
The S&P 500 rose about 0.8% to roughly 6,946, marking a second straight…
GeoVax’s (NASDAQ: GOVX) latest move to lock down combination rights for its Gedeptin cancer platform reads less like a routine licensing notice and more like an oncology strategy upgrade—complete with optionality, IP leverage, and a quietly ambitious grab for front-line real estate…
GeoVax Labs (NASDAQ: GOVX) is stepping into 2026 talking like an inflection‑year story—and, unusually for biotech, it has the clinical, regulatory and manufacturing pieces to at least justify the wardrobe change. While capital remains tight, the company is pairing late‑stage Mpox vaccine…
US stocks extended last week’s relief rally on Monday, with megacap tech doing most of the heavy lifting while value names tried to remember what outperformance felt like. Investors spent the session toggling between AI euphoria, tariff anxiety and a yield curve…
Wall Street closed the week ending Feb. 6, 2026 looking a bit like a trader after a rough options expiry: bruised, but suddenly energetic once the bell rang on Friday. The Dow finally cracked the 50,000 mark in a more-than-1,000‑point sprint, while…
US stocks spent Thursday behaving like a slightly over-caffeinated, negative economist: plenty of motion & an overall negative conviction, as investors digested another wave of tech volatility, macro cross-currents, and a busy new-issue calendar heading into Friday’s jobs data. As evidence the…
In a fitting summary for the day, hard assets glittered, AI narratives wobbled, and Eli Lilly proved that in 2026, the market’s favorite growth story is just as likely to come from the medicine cabinet as from the data center. Broadly on…
U.S. stocks lost a bit of altitude on Tuesday, as the AI trade paused for breath and investors briefly remembered that prices can, in fact, go down. But that is not all of the story as the small caps on the Russell…
U.S. stocks launched February with a flourish, as major indexes shrugged off weekend volatility in commodities and crypto to end Monday sharply higher.
S&P 500: Brushing Past Its Nerves
The S&P 500 spent the day flirting with record territory, ultimately closing just…
